[1]倪斐,许萍,潘杰.小剂量利妥昔单抗联合银屑病1号方治疗系统性红斑狼疮疗效观察[J].西部中医药,2021,34(08):107-109.[doi:10.12174/j.issn.2096-9600.2021.08.23]
　NI Fei,XU Ping,PAN Jie.Clinical Observation on Low Dose Rituximab Combined with Psoriasis No.1 Formula in Treating Systemic Lupus Erythematosus[J].Western Journal of Traditional Chinese Medicine,2021,34(08):107-109.[doi:10.12174/j.issn.2096-9600.2021.08.23]
点击复制

小剂量利妥昔单抗联合银屑病1号方治疗系统性红斑狼疮疗效观察

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
34
期数:
2021年08期
页码:
107-109
栏目:
出版日期:
2021-08-15

文章信息/Info

Title:
Clinical Observation on Low Dose Rituximab Combined with Psoriasis No.1 Formula in Treating Systemic Lupus Erythematosus
作者:
倪斐1, 许萍2, 潘杰2
1.溧阳市人民医院,江苏 溧阳 213300
2.江苏省人民医院溧阳分院
Author(s):
NI Fei1, XU Ping2, PAN Jie2
1.Liyang City People's Hospital, Liyan 213300, China
2.Liyang Branch of Jiangsu Provincial People's Hospital
关键词:
系统性红斑狼疮; 利妥昔单抗; 银屑病1号方
Keywords:
SLE; rituximab; psoriasis No.1 formula
分类号:
R593.24+1
DOI:
10.12174/j.issn.2096-9600.2021.08.23
摘要:
目的观察小剂量利妥昔单抗联合银屑病1号方治疗系统性红斑狼疮的临床疗效。 方法选择81例系统性红斑狼疮患者，随机分为观察组（40例）和对照组（41例）。对照组采用小剂量利妥昔单抗治疗，观察组联用银屑病1号方，观察两组临床疗效，血清肿瘤坏死因子α（tumor necrosis factor-α，TNF-α）、白细胞介素17（interleukin-17，IL-17）、免疫球蛋白G（immunoglobulin G，IgG）、抗核抗体（antinuclear antibody，ANA）、S100钙结合蛋白P（S100 calcium binding protein，S100P）、泌乳素（prolactin，PRL）、血清补体C3、环氧二十碳三烯酸（epoxyeicosatrienoic acids，EET）水平。 结果总有效率观察组［80.00%（32/40）］明显高于对照组［58.54%（24/41）］（P＜0.05）；治疗后，两组TNF-α、IL-17、IgG、ANA、S100P、PRL水平均治疗前明显降低，血清补体C3、EET水平明显升高（P＜0.05），且观察组较对照组改善更明显（P＜0.05）。 结论小剂量利妥昔单抗联合银屑病1号方治疗系统性红斑狼疮疗效显著，不仅能改善免疫功能指标，还能改善疾病相关血清因子水平。
Abstract:
ObjectiveTo study clinical effects of low dose rituximab and psoriasis No.1 formula in treating systemic lupus erythematosus(SLE). MethodsAll 81 SLE patients were chosen and randomized into the observation group(40 cases) and the control group(41 cases).The control group adopted low dose rituximab,and the observation group psoriasis No.1 formula, to observe clinical effects,the levels of TNF-α,IL-17,IgG,ANA,S100P, PRL, serum complement C3 and EET in two groups. ResultsTotal effective rate of the observation group was[80.00%(32/40)], higher than[58.54%(24/41)] of the control group (P<0.05); after treating, the levels of TNF-α,IL-17, IgG, ANA, S100P and PRL reduced notably in the serum of both groups than these before treating(P<0.05), the levels of C3 and EET in the serum increased obviously(P<0.05), and the improvement of the observation group was more notable compared with that of the control group(P<0.05). ConclusionLow dose rituximab and psoriasis No.1 own notable effects in treating SLE, it could not only improve immune function indexes,but also improve the levels of disease-related serum factors.

相似文献/References:

[1]金 燕.情志护理对系统性红斑狼疮患者抑郁焦虑的影响[J].西部中医药,2014,27(09):135.
[2]张志峰.三氧化二砷治疗系统性红斑狼疮的实验研究进展[J].西部中医药,2018,31(08):153.
　ZHANG Zhifeng.Experimental Progress of Arsenous Oxide in Treating SLE[J].Western Journal of Traditional Chinese Medicine,2018,31(08):153.
[3]成雪莉,钟正宏,赖家文,等.中药联合糖皮质激素治疗系统性红斑狼疮系统评价与Meta分析[J].西部中医药,2026,39(04):68.[doi:10.12174/j.issn.2096-9600.2026.04.15]
　CHENG Xueli,ZHONG Zhenghong,LAI Jiawen,et al.Systematic Review and Meta-Analysis of Chinese Herbal Medicine Combined with Glucocorticoids in the Treatment of Systemic Lupus Erythematosus[J].Western Journal of Traditional Chinese Medicine,2026,39(08):68.[doi:10.12174/j.issn.2096-9600.2026.04.15]
[4]李清扬.基于CiteSpace对治疗系统性红斑狼疮知识图谱的分析[J].西部中医药,2020,33(06):75.[doi:10.12174/j.issn.1004-6852.2020.06.20]
　LI Qingyang.An Analysis of Knowledge Map of Treating Systemic Lupus Erythematosus Based on CiteSpace[J].Western Journal of Traditional Chinese Medicine,2020,33(08):75.[doi:10.12174/j.issn.1004-6852.2020.06.20]

备注/Memo

备注/Memo:
倪斐（1989—），女，主治医师。研究方向：系统性红斑狼疮的诊治。江苏省卫生计生委员会项目（zg201619）。
更新日期/Last Update: 2021-08-15